期刊文献+

沙格列汀治疗2型糖尿病的疗效和安全性评价 被引量:2

下载PDF
导出
摘要 目的对沙格列汀在2型糖尿病患者治疗中的疗效及安全性予以探讨。方法随机选取我院2016年8月至2017年3月间收治的2型糖尿病患者40例,将其随机均分为对照组与观察组,为对照组患者应用单纯的二甲双胍开展治疗,观察组在对照组的基础上加用沙格列汀开展治疗,对比分析两组患者的临床疗效及不良反应发生情况。结果观察组的临床治疗总有效率明显高于对照组,体质量指数(BMI)、糖化血红蛋白(Hb A1c)、餐后2h血糖(2h PBG)、空腹血糖(FBG)等指标存在明显差异,且P<0.05,差异具有统计学意义;两组患者不良反应发生情况差异不具备统计学意义。结论在为2型糖尿病患者开展治疗的过程中,应用沙格列汀开展治疗,能够取得良好的临床治疗效果,且无严重的不良反应,具有良好的临床疗效及治疗安全性,值得在临床应用中推广。
作者 李进
出处 《海峡药学》 2018年第2期185-186,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献5

二级参考文献40

  • 1何寒青,陈坤.Meta分析中的异质性检验方法[J].中国卫生统计,2006,23(6):486-487. 被引量:102
  • 2Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibi- tors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010, 30(5): 463-484.
  • 3Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook, org.
  • 4Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes, Obesity And Metabolism, 2008, 10(5): 376-386.
  • 5Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes:A Randomised Controlled Trial. Int J Clin Pract, 2009, 63(9): 1395-1406.
  • 6DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxzgliptin when added to metformin therapy in patients with inad- equately controlled type 2 diabetes with metformin alone. Diabetes Care, 2009, 32(9): 1649-1655.
  • 7Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidin- edione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab, 2009, 94(12): 4810-4819.
  • 8Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin, 2009, 25(10): 2401-2411.
  • 9National Institute for health and clinical excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87. London: NICE, 2009.
  • 10Henry RR, Smith SR, Schwartz SL, et al. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 dia- betes. Diabetes Obes Metab, 2011, 13(9): 850-858.

共引文献228

同被引文献20

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部